Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MGMT | P16455 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31395761 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1MGMT | |
| SCHEMBL13554631 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1MGMT | |
| SCHEMBL16437097 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1MGMT | |
| SCHEMBL16899909 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1MGMT | |
| SCHEMBL14763470 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1MGMT | |
| SCHEMBL17836995 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1MGMT | |
| SCHEMBL18576097 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1MGMT | |
| SCHEMBL13449860 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1MGMT | |
| SCHEMBL16899883 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1MGMT | |
| SCHEMBL31577560 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1MGMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 546 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119564853-A | Preparation method and application of targeted fusobacterium nucleatum in-situ self-assembled photo-thermal nano material | 天津工业大学 | 2025-03-07 | — | — | CN | claimed |
| US-20230374566-A1 | METHODS OF IDENTIFYING PROTEIN BINDING SITES ON RNA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-23 | — | — | US | claimed |
| EP-4217364-A1 | METHODS OF IDENTIFYING PROTEIN BINDING SITES ON RNA | The Regents of the University of California (US) | 2023-08-02 | — | — | EP | claimed |
| CN-116406379-A | anti-FGFR 2 antibodies and methods of use thereof | 瑞泽恩制药公司 | 2023-07-07 | — | — | CN | claimed |
| CN-115997016-A | Composition comprising nucleic acid nanoparticles having modular functional groups | 西克斯福德生物科学有限公司 | 2023-04-21 | — | — | CN | claimed |
| CN-111635496-B | Temperature-sensitive cell culture plate and preparation method thereof | 洛阳理工学院 | 2022-11-04 | — | — | CN | claimed |
| CN-115175737-A | Bispecific antigen binding molecules that bind HER2 and methods of use thereof | 瑞泽恩制药公司 | 2022-10-11 | — | — | CN | claimed |
| WO-2022067036-A1 | METHODS OF IDENTIFYING PROTEIN BINDING SITES ON RNA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-03-31 | — | — | WO | claimed |
| EP-3707193-A1 | DENDRIMER DELIVERY SYSTEM AND METHODS OF USE THEREOF | The Johns Hopkins University (US) | 2020-09-16 | — | — | EP | claimed |
| CN-111615528-A | Dendrimer delivery systems and methods of use thereof | 约翰霍普金斯大学 | 2020-09-01 | — | — | CN | claimed |
| CN-110240611-B | Preparation method and application of photosensitizer targeting EGFR (epidermal growth factor receptor) over-expression tumor cell endoplasmic reticulum | 福州大学 | 2020-08-11 | — | — | CN | claimed |
| US-20190142964-A1 | DENDRIMER DELIVERY SYSTEM AND METHODS OF USE THEREOF | Ashvattha Therapeutics, Inc. | 2019-05-16 | — | — | US | claimed |
| US-20260139272-A1 | LACTAM-MODIFIED ADENO-ASSOCIATED VIRUS VECTORS | COAVE THERAPEUTICS (FR) | 2026-05-21 | — | — | US | disclosed |
| EP-4744668-A2 | POLYNUCLEOTIDE CONSTRUCTS | Sirius Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| CN-122005838-A | CD 38-targeted antibody-drug conjugate and preparation method and application thereof | 上海科技大学 | 2026-05-12 | — | — | CN | disclosed |
| US-20260125410-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | UNIV YALE (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2009043986-A1 | THREE-FUNCTIONAL PSEUDO-PEPTIDIC REAGENT, AND USES AND APPLICATIONS THEREOF | UNIVERSITE DE ROUEN (FR) | 2009-04-09 | — | — | WO | disclosed |
| US-20090036353-A1 | Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers | NOVO NORDISK A/S (DK) | 2009-02-05 | — | — | US | disclosed |
| US-20090036431-A1 | Cytotoxic Agents Comprising New Tomaymycin Derivatives | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | US | disclosed |
| US-20080207913-A1 | Poly(ethylene glycol) containing chemically disparate endgroups | INTEZYNE TECHNOLOGIES (US) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036431-A1 | Cytotoxic Agents Comprising New Tomaymycin Derivatives | TOMM70, TOMM34, TOMM40 | MEN1 2584/4885KMT2A 4180/4885TSHR 3895/4885 |
| US-20190142964-A1 | DENDRIMER DELIVERY SYSTEM AND METHODS OF USE THEREOF | TLR3, CD40LG, OXGR1 | MEN1 3686/4885KMT2A 2573/4885TSHR 2190/4885 |
| US-20260125410-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | ASGR1, COL2A1, FCGR2A | MEN1 4446/4885KMT2A 3413/4885TSHR 126/4885 |
| US-20090036353-A1 | Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers | INSR, IAPP, IGF1R | MEN1 278/4885KMT2A 4457/4885TSHR 323/4885 |
| US-20080207913-A1 | Poly(ethylene glycol) containing chemically disparate endgroups | GNE, EPRS1, ALG1 | MEN1 2092/4885KMT2A 3924/4885TSHR 3867/4885 |
| US-20260139272-A1 | LACTAM-MODIFIED ADENO-ASSOCIATED VIRUS VECTORS | OXA1L, ARCN1, ACTN1 | MEN1 1256/4885KMT2A 502/4885TSHR 2529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.